Gilead's three-drug HIV regimen wins European panel approval
(Reuters) - Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.
from Reuters: Health News https://reut.rs/2FkcSKb
http://bit.ly/2zwRqiM